Cerence AI has been recognized as the Growth and Innovation Index leader in Frost & Sullivan's 2026 Frost Radar for AI-Powered In-Car Assistants, highlighting its advanced automotive AI platform, Cerence xUI®. This platform enables natural conversation and multi-agent orchestration, allowing automakers to integrate sophisticated AI while maintaining control over branding and data. The recognition underscores Cerence's hybrid edge-cloud architecture and OEM-first approach, positioning it as a visionary leader in automotive AI innovation amid growing competition from Big Tech. This leadership is expected to drive further advancements and adoption of AI in vehicles, enhancing driver experience and safety.
Cerence AI's recognition as a leader in AI-powered in-car assistants is presented here with Pluang's Technology sector market data as of Oct 19, 2026 19:31 WIB. Of 150 priced Technology-sector US stocks tradable on Pluang, 93 rose and 46 fell today. Notable movers include CRDO at USD 177.83 with a 4.79% increase, CRSR at USD 13.40 with a 4.77% increase, and MRVL at USD 238.15 with a 4.53% increase, with CRDO showing the highest single-day gain among them.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
